Director Maxine Gowen Equity Awards and Vesting at Aclaris Therapeutics

This Form 4 filing reports equity transactions for Aclaris Therapeutics director Maxine Gowen. On June 4, 2026, Gowen received 42,350 stock options with an exercise price of $4.71 that vest monthly starting July 4, 2026, and 10,987 restricted stock units vesting on June 4, 2027. On June 5, 2026, 11,580 restricted stock units vested and were converted to common stock, increasing her direct holdings to 33,334 shares. The transactions were made under the company's non-employee director compensation policy and equity incentive plan. The stock options expire on June 3, 2036. These awards represent standard director compensation and equity incentive arrangements.